Copyright
©The Author(s) 2019.
World J Hepatol. May 27, 2019; 11(5): 421-441
Published online May 27, 2019. doi: 10.4254/wjh.v11.i5.421
Published online May 27, 2019. doi: 10.4254/wjh.v11.i5.421
Figure 3 Projected chronic hepatitis C-related medical costs in China in the absence of effective hepatitis C virus treatment.
Estimation based on annual data (2005–2013) of hepatitis C virus infection cases from the Chinese Center for Disease Control and Prevention; graph generated using data reported in Wei et al[88], 2015. HCC: Hepatocellular carcinoma.
- Citation: Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol 2019; 11(5): 421-441
- URL: https://www.wjgnet.com/1948-5182/full/v11/i5/421.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i5.421